Open access
Open access
Powered by Google Translator Translator

Covid-19

SARS-CoV-2 is associated with changes in brain structure in UK Biobank.

9 Mar, 2022 | 09:53h | UTC

SARS-CoV-2 is associated with changes in brain structure in UK Biobank – Nature

Commentary:

Brain changes after COVID revealed by imaging – Nature

Even mild cases of COVID-19 can leave a mark on the brain, such as reductions in gray matter – a neuroscientist explains emerging research – The Conversation

Scans reveal how Covid may change the brain – BBC

 

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain.

8 Mar, 2022 | 08:56h | UTC

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

 

Study shows the number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance”.

8 Mar, 2022 | 08:57h | UTC

News Release: Number of covid-19 infections missed by lateral flow tests “substantial enough to be of clinical importance,” warn experts – BMJ

Original Study: SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis – The BMJ

Commentaries:

Lateral flow tests may be missing ‘substantial’ number of COVID-19 infections – Imperial College London

Self-testing for asymptomatic non-contacts using rapid antigen tests—is this leading to a cost effective reduction in infection transmission? – The BMJ

 

[News release – not published yet] New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials.

8 Mar, 2022 | 08:53h | UTC

Commentary: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

News Release: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

 

The next variant: three key questions about what’s after Omicron.

8 Mar, 2022 | 08:54h | UTC

The next variant: three key questions about what’s after Omicron – Nature

 

Systematic Review: Anticoagulants for people hospitalized with COVID‐19.

7 Mar, 2022 | 00:48h | UTC

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Summary: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

Related: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

 

COVID-19: How Omicron overtook Delta in three charts.

7 Mar, 2022 | 00:46h | UTC

COVID-19: How Omicron overtook Delta in three charts – Nature

 

Review articles: Cutaneous manifestations of SARS-CoV-2 infection.

7 Mar, 2022 | 00:38h | UTC

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

 

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

4 Mar, 2022 | 10:09h | UTC

News Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Original study: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Commentaries:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Related:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Commentary from the author on Twitter (thread – click for more)

 

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.

4 Mar, 2022 | 10:07h | UTC

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis – The Lancet

Invited Commentary: Understanding of COVID-19 from infection–fatality ratio – The Lancet

 

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators.

4 Mar, 2022 | 10:04h | UTC

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021 – The Lancet

Commentaries:

Gender equality and COVID-19: act now before it is too late – The Lancet

Social and economic effects of the COVID-19 pandemic threaten to reverse progress towards gender equality: study – The Lancet

 

Commentary on Twitter (thread – click for more)

 

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Related:

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Commentary on Twitter

 

WHO: COVID-19 pandemic triggers a 25% increase in the prevalence of anxiety and depression worldwide.

3 Mar, 2022 | 09:44h | UTC

News Release: COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide – World Health Organization

Scientific Brief: Mental health and COVID-19: Early evidence of the pandemic’s impact – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

M-A: Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19.

3 Mar, 2022 | 08:49h | UTC

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis – BMJ Medicine

Editorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine

Related study (just published): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open

 

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

3 Mar, 2022 | 08:43h | UTC

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics

Commentary: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI

Related:

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.

3 Mar, 2022 | 08:46h | UTC

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations – Nature Reviews Rheumatology

 

Commentary on Twitter

 

Prescribing Nirmatrelvir–Ritonavir for Covid-19: How to recognize and manage drug–drug interactions.

2 Mar, 2022 | 09:01h | UTC

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

Related:

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Pfizer antiviral pills may be risky with other medications – NBC News

The New COVID-19 Pill, Paxlovid, Interacts with Many Medications: Cardiac Patients Take Note – The Skeptical Cardiologist

 

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.

2 Mar, 2022 | 09:03h | UTC

Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week – Journal of the American College of Cardiology

Commentary: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology

 

Wuhan market was epicenter of pandemic’s start, studies suggest.

2 Mar, 2022 | 08:59h | UTC

Wuhan market was epicentre of pandemic’s start, studies suggest – Nature

Related:

[Preprint] SARS-like viruses may jump from animals to people hundreds of thousands of times a year.

Did the coronavirus jump from animals to people twice? – Nature

The Origins of SARS-CoV-2: A Critical Review.

The animal origin of SARS-CoV-2 – “Trading of animals susceptible to bat coronaviruses is the likely cause of the COVID-19 pandemic”.

Fauci says natural origins theory of coronavirus is still the most likely.

 

Commentary on Twitter

 

Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.

1 Mar, 2022 | 08:58h | UTC

Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update – Anaesthesia

Related:

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

 

[Preprint] Study shows significantly reduced effectiveness of the Pfizer vaccine in children 5 to 11 after the emergency of the Omicron variant.

1 Mar, 2022 | 08:54h | UTC

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Commentaries:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

 

CDC issues long-awaited new guidance on when to wear masks.

27 Feb, 2022 | 22:45h | UTC

CDC issues long-awaited new guidance on when to wear masks – STAT

See also: As mask mandates fade, experts say use of masks likely will not – STAT

 

ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2.

27 Feb, 2022 | 22:47h | UTC

ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2 – Clinical Microbiology and Infection

 

Consensus Statement: Successfully implementing digital health to ensure future global health security during pandemics.

25 Feb, 2022 | 11:34h | UTC

Successfully Implementing Digital Health to Ensure Future Global Health Security During Pandemics: A Consensus Statement – JAMA Network Open

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.